HCW Biologics Inc (HCWB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, HCW Biologics Inc (HCWB) has a cash flow conversion efficiency ratio of -0.534x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.97 Million) by net assets ($7.43 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see HCW Biologics Inc (HCWB) market capitalisation for the company's overall valuation and market capitalisation.
HCW Biologics Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how HCW Biologics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
HCW Biologics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of HCW Biologics Inc ranked by their cash flow conversion efficiency. Explore earnings quality score of HCW Biologics Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ranplan Group
ST:RPLAN
|
16.007x |
|
Minco Capital Corp
V:MMM
|
0.009x |
|
South HARZ Potash Ltd
AU:SHP
|
-0.877x |
|
Social Housing REIT plc
LSE:SOHO
|
0.034x |
|
NR 21 S.A.
PA:NR21
|
-0.008x |
|
Evogene
TA:EVGN
|
-0.220x |
|
StageZero Life Sciences Ltd
TO:SZLS
|
0.013x |
|
Ximen Mining Corp
V:XIM
|
0.086x |
Annual Cash Flow Conversion Efficiency for HCW Biologics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of HCW Biologics Inc from 2019 to 2025. View HCW Biologics Inc stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.76 Million | $-13.39 Million | -4.844x | -330.49% |
| 2024-12-31 | $-6.77 Million | $-14.23 Million | 2.101x | +225.65% |
| 2023-12-31 | $13.46 Million | $-22.51 Million | -1.672x | -502.70% |
| 2022-12-31 | $37.43 Million | $-10.39 Million | -0.277x | -29.43% |
| 2021-12-31 | $51.19 Million | $-10.98 Million | -0.214x | +70.41% |
| 2020-12-31 | $14.40 Million | $-10.43 Million | -0.725x | +3.61% |
| 2019-12-31 | $9.00 Million | $-6.77 Million | -0.752x | -- |
About HCW Biologics Inc
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and … Read more